S5297Referred to Committee

American Pharmaceutical Security Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-08-06
Introduced
1
Cosponsors
S
ⓘ
Type

Sponsor

Adam B. Schiff
Adam B. Schiff
Democrat · CA · Senator
Votes with party: 82.3% (868 recorded votes)

Full profile: /officials/S001150

Source: Congress.gov · FEC

Cosponsors (1)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Finance.

2026-08-06

Source: Congress.gov

Committee Activity

Currently in

Plain-English Summary

Plain-English summary pending. Introduced on 2026-08-06. Check back soon — summaries are generated as bills progress through Congress.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 5297 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 5297 To require the Administrator of the Centers for Medicare & Medicaid Services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES August 6, 2026 Mr. Schiff (for himself and Mr. Scott of Florida) introduced the following bill; which was read twice and referred to the Committee on Finance _______________________________________________________________________ A BILL To require the Administrator of the Centers for Medicare & Medicaid Services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``American Pharmaceutical Security Act''. SEC. 2. REPORT ON MARKETS FOR API AND KEY STARTING MATERIALS. (a) In General.--Not later than 1 year after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the ``Administrator'') shall submit to Congress a report on its findings and policy recommendations regarding the use of coverage and reimbursement authorities to protect the markets of the United States and its allies for active pharmaceutical ingredients and key starting materials and reduce direct and indirect dependence on foreign adversaries (as described in section 791.4 of title 15, Code of Federal Regulations (or any successor regulations)) for such ingredients and materials. (b) Contents.--The report under subsection (a)-- (1) may include-- (A) recommendations for price floor commitments in support of domestic manufacturing of active pharmaceutical ingredients and key starting materials to protect investments in the domestic markets of such ingredients and materials against nonmarket practices and price manipulation; and (B) recommendations that would prioritize domestically manufactured active pharmaceutical ingredients and key starting materials over foreign manufactured active pharmaceutical ingredients and key starting materials when a domestic source for the applicable ingredient or material exists; and (2) shall identify any existing gaps in data and information related to the origin and ownership of active pharmaceutical ingredients and key starting materials that the Administrator would need to implement the recommendations included in the report. <all>
Open clean-text viewRead on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.